Altamira Therapeutics Files May 2024 6-K Report

TL;DR

Altamira Therapeutics (ALTA) filed its May 6-K, standard disclosure, nothing major.

AI Summary

Altamira Therapeutics Ltd. filed a Form 6-K on May 16, 2024, reporting information for the month of May 2024. The company, formerly known as Auris Medical Holding Ltd., is incorporated in Bermuda and operates in the Pharmaceutical Preparations sector. This filing is made pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

Why It Matters

This filing provides routine updates and disclosures for Altamira Therapeutics Ltd., which is important for investors to stay informed about the company's ongoing compliance and reporting obligations.

Risk Assessment

Risk Level: low — This filing is a routine report and does not contain significant new financial information or material events.

Key Players & Entities

• Altamira Therapeutics Ltd. (company) — Registrant
• Auris Medical Holding Ltd. (company) — Former company name
• 20240516 (date) — Filing date

FAQ

Filing Documents

• ea0206215-6k_altamira.htm (6-K) — 15KB
• 0001213900-24-044325.txt ( ) — 17KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-36582 Altamira Therapeutics Ltd. (Exact name of registrant as specified in its charter) Clarendon House, 2 Church Street Hamilton HM 11, Bermuda (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F INCORPORATION BY REFERENCE This Report on Form 6-K, including the exhibit to this Report on Form 6-K, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Numbers 333-228121 , 333-249347 , 333-261127 , 333-264298 , 333-267584 , 333-272338 and 333-276427 ) and Form S-8 (Registration Numbers 333-232735 , 333-252141 and 333-278595 ) of Altamira Therapeutics Ltd. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Altamira Therapeutics Ltd. Date: May 16, 2024 By: /s/ Thomas Meyer Name: Thomas Meyer Title: Chief Executive Officer 2 Annual General Meeting Results On May 16, 2024 Altamira Therapeutics Ltd. (the “Company”) held its Annual General Meeting of Shareholders. Based on the presence in person or by proxy of holders of the Company’s outstanding ordinary shares constituting a quorum, each of the agenda items submitted to a vote of the shareholders was duly adopted by the requisite majority in accordance with the Company’s Bye-Laws: Agenda Item 1: Election of the Members of the Board of Directors The Company’s shareholders elected Messrs. Thomas Meyer, Alain Munoz, Mats Peter Blom and Dominik Lysek, as members of the Board of Directors, each for a term of one year ending upon completion of the 2025 Annual General Meeting (or until their respective successors are elected). Agenda Item 2: Appointment of Auditors The Company’s shareholders re-elected BDO AG, Zurich, as auditors of Altamira Therapeutics Ltd. for the 2024 financial year. Agenda Item 3: Compensation of the Board of Directors and the Executive Officers The Company’s shareholders approved, on a non-binding advisory basis, the 2023 Board of Directors’ and Executive Officers’ compensation. Agenda Item 4: Reduction in the Share Premium Account The Company’s shareholders approved the reduction in the share premium account of the Company with effect from May 16, 2024 by USD 38,219,314.44 and to credit the amount of the reduction to the contributed surplus account of the Company. Agenda Item 5: Increase of the Authorized Share Capital The Company’s shareholders approved to increase the authorized share capital of the Company from USD 12,000 divided into 5,000,000 common shares of USD 0.002 each and 20,000,000 preference shares of USD 0.0001 each to USD 202,000 divided into 100,000,000 common shares of USD 0.002 each and 20,000,000 preference shares of USD 0.0001 each, by the creation of an additional 95,000,000 common shares of USD 0.002 each ranking pari-passu with the existing common shares of the Company. 3

View Full Filing

View this 6-K filing on SEC EDGAR